Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lb Pharmaceuticals (LBRX) Amortizatization of Intangibles (2024 - 2026)

Lb Pharmaceuticals' quarterly Amortizatization of Intangibles came in at -$17000.0 in Q1 2026, down 241.67% year-on-year from $12000.0 in Q1 2025, and little changed quarter-over-quarter from -$17000.0 in Q4 2025.

Lb Pharmaceuticals has reported Amortizatization of Intangibles for 3 years, with the latest figure at -$17000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Amortizatization of Intangibles fell 241.67% year-over-year to -$17000.0; the trailing twelve-month figure through Mar 2026 stood at $39000.0 (changed N/A YoY), and the FY2025 full-year result was -$261000.0, down 867.65% from the prior year.
  • Amortizatization of Intangibles for Q1 2026 stood at -$17000.0, roughly flat from -$17000.0 in the prior quarter.
  • The five-year high for Amortizatization of Intangibles was $61000.0 in Q4 2024, with the low at -$17000.0 in Q4 2025.
  • Average Amortizatization of Intangibles over 3 years is $9750.0, with a median of -$2500.0 recorded in 2025.
  • Year-over-year, Amortizatization of Intangibles tumbled 127.87% in 2025 and tumbled 241.67% in 2026.
  • Tracing LBRX's Amortizatization of Intangibles over 3 years: stood at $61000.0 in 2024, then plunged by 127.87% to -$17000.0 in 2025, then changed by 0.0% to -$17000.0 in 2026.
  • The last three Amortizatization of Intangibles figures came in at -$17000.0 (Q1 2026), -$17000.0 (Q4 2025), and $12000.0 (Q1 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Amortizatization of Intangibles (Qtr)
1 Quantum Biopharma 1,216,509.61 Bn 1,216,509.61 Bn - 13,267.00
2 Alterity Therapeutics 764,224.41 Bn 764,224.38 Bn - -
3 Legend Biotech 2,716.00 Bn 2,715.71 Bn 242.10 Mn -
4 Nanobiotix 2,248.83 Bn 2,248.77 Bn - -
5 Akari Therapeutics 1,951.18 Bn 1,951.17 Bn - -
6 Vertex Pharmaceuticals 113.69 Bn 106.44 Bn 2.59 Bn -
7 Evaxion A 64.16 Bn 64.14 Bn - -
8 Regeneron Pharmaceuticals 63.94 Bn 55.18 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 40.13 Bn 37.12 Bn 959.66 Mn -
10 Lb Pharmaceuticals 789.92 Mn 789.92 Mn - -17,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -17,000.00
Mar 31, 2026 -17,000.00
Dec 31, 2025 -17,000.00
Dec 31, 2025 -17,000.00
Mar 31, 2025 12,000.00
Mar 31, 2025 12,000.00
Dec 31, 2024 61,000.00
Dec 31, 2024 61,000.00